Patents Assigned to National Cancer Center
  • Publication number: 20240168026
    Abstract: The present invention provides a convenient and noninvasive detection method for assisting in the determination of pancreatic cystic tumor to be benign or malignant, and a kit for detection therefor. Specifically, the present invention provides a method for assisting in the determination of malignant pancreatic cystic tumor, the method comprising the steps of measuring in vitro the amount of APOA2-AT protein or/and APOA2-ATQ protein present in a body fluid sample of a test subject having pancreatic cystic tumor, and assisting in determining the pancreatic cystic tumor to be benign or malignant on the basis of the amount, and a kit for assisting in the determination of malignant pancreatic cystic tumor, the kit being directed to measuring the amount of APOA2-AT protein or/and APOA2-ATQ protein and being usable in the method.
    Type: Application
    Filed: March 22, 2022
    Publication date: May 23, 2024
    Applicants: Toray Industries, Inc., NATIONAL CANCER CENTER
    Inventors: Michimoto Kobayashi, Hideki Kawai, Asako Sogame, Kazufumi Honda
  • Publication number: 20240166736
    Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.
    Type: Application
    Filed: December 26, 2023
    Publication date: May 23, 2024
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki TENDA, Masatoshi YURI, Daisuke YAMAJUKU, Takeshi TSUTSUMI, Yuko KUSUZAKI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
  • Publication number: 20240141439
    Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Makiko YOSHIMOTO, Hiroko SUDO, Atsuko MIYANO, Satoko KOZONO, Takahiro OCHIYA, Hiroyuki FUJIMOTO, Fumihiko URABE, Juntaro MATSUZAKI
  • Publication number: 20240123092
    Abstract: Provided is a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and a composition for photodynamic diagnosis or treatment including the same. The conjugate generates no fluorescent signal and reactive oxygen in normal tissues or during the circulation in the blood by quenching a fluorescent signal and reactive oxygen generation ability of the photosensitizer. After the conjugate is selectively absorbed into target cells, a linker is degraded in cells to increase the distance between tryptophan included in the peptide and the photosensitizer, and the quenching action is terminated to generate a strong fluorescence signal and induce active generation of reactive oxygen. The conjugate has high tissue permeability, shows a high photodynamic therapeutic effect in only target cells while being safe in normal cells, and can obtain a good diagnostic image having a high ratio of target signal to background.
    Type: Application
    Filed: September 15, 2023
    Publication date: April 18, 2024
    Applicant: NATIONAL CANCER CENTER
    Inventors: Yong-Doo CHOI, Ji-Su Kim, Hyun Jin Kim
  • Publication number: 20240122941
    Abstract: The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the formulae are as set forth in the specification) or a pharmaceutically acceptable salt thereof can have a therapeutic and/or prophylactic effect on SWI/SNF complex-dysfunction cancer. A pharmaceutical composition, which is for treating and/or preventing cancer and contains a CBP/P300 inhibitor, can be provided. The cancer may be SWI/SNF complex-dysfunction cancer. The SWI/SNF complex-dysfunction cancer may be BAF complex-dysfunction cancer. The BAF complex-dysfunction cancer may be SMARC-deficient cancer, ARID-deficient cancer, or SS18-SSX fusion cancer. The SMARC-deficient cancer may be SMARCB1-deficient cancer, SMARCA2-deficient cancer, SMARCA4-deficient cancer, or SMARCA2/A4-deficient cancer.
    Type: Application
    Filed: December 24, 2021
    Publication date: April 18, 2024
    Applicants: NATIONAL CANCER CENTER, Sumitomo Pharma Co., Ltd.
    Inventors: Hideaki OGIWARA, Mariko SASAKI
  • Patent number: 11959144
    Abstract: An object of the present invention is to provide a kit or a device for the detection of prostate cancer and a method for detecting prostate cancer. The present invention provides a kit or a device for the detection of prostate cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting prostate cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: April 16, 2024
    Assignees: Toray Industries, Inc., National Cancer Center
    Inventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Takahiro Ochiya, Nobuyoshi Kosaka
  • Patent number: 11957300
    Abstract: An information processing apparatus (2000) detects an abnormal region (30) from a moving image frame (14). The abnormal region (30) is a region that is estimated to represent an abnormal part inside a body of a subject. The information processing apparatus (2000) generates and outputs output information based on the number of detected abnormal regions (30).
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 16, 2024
    Assignees: NEC CORPORATION, NATIONAL CANCER CENTER
    Inventors: Ikuma Takahashi, Maki Sano, Kimiyasu Takoh, Motoyasu Okutsu, Chiemi Tanaka, Masahiro Saikou, Hitoshi Imaoka, Kenichi Kamijo, Ryuji Hamamoto, Yutaka Saito, Masayoshi Yamada
  • Publication number: 20240111804
    Abstract: A processor receives an input of finding information indicating at least one finding, which is desired to be searched for, on a query base image, which includes a part desired to be searched for and is a source of a query image, to derive the query image to which the finding has been added, derives at least one added finding feature amount indicating an image feature for the added finding, and derives a query normal feature amount indicating an image feature for a normal region included in the part in the query base image. The processor derives similarities between the query image and a plurality of reference images including findings on the basis of comparisons between the added finding feature amount and the query normal feature amount and the like with reference to an image database in which the plurality of reference images have been registered and extracts the reference image that is similar to the query image as a similar image from the image database on the basis of the similarities.
    Type: Application
    Filed: December 14, 2023
    Publication date: April 4, 2024
    Applicants: NATIONAL CANCER CENTER, FUJIFILM Corporation
    Inventors: Kazuma KOBAYASHI, Mototaka MIYAKE, Ryuji HAMAMOTO
  • Publication number: 20240102108
    Abstract: Disclosed is a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, including a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, including measuring the miRNA(s) in vitro.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 28, 2024
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoko KOZONO, Hitoshi NOBUMASA, Satoshi KONDOU, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Publication number: 20240101678
    Abstract: Provided are CAR-T compositions that are directed to HLA-DR. Certain provided HLA-DR CAR compositions exhibit low affinity for a polymorphic region of HLA-DR of a subject. Various in vitro and in vivo methods and reagents related to HLA-DR CAR-T are also provided. Methods described herein can include, for example, characterization of HLA-DR binding, proliferation of T-cells, as well as prevention and/or therapeutic treatment of cancer using a HLA-DR CAR-T composition provided herein.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 28, 2024
    Applicants: EUTILEX CO., LTD., NATIONAL CANCER CENTER
    Inventors: Byoung S. KWON, Chungyong HAN
  • Publication number: 20240093311
    Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 21, 2024
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Takahiro OCHIYA, Nobuyoshi KOSAKA, Makiko ONO, Kenji TAMURA
  • Publication number: 20240081796
    Abstract: A full-thickness resection method for a gastrointestinal tract includes forming a pair of first markings in surrounding tissue on both sides of a lesion to sandwich the lesion therebetween; performing a full-thickness resection to a portion including the lesion; identifying a pair of suture locations in the vicinity of the pair of first markings; and suturing the pair of first suture locations.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 14, 2024
    Applicants: OLYMPUS CORPORATION, NATIONAL CANCER CENTER
    Inventors: Arimasa SUGIMOTO, Satoru NONAKA
  • Publication number: 20240085426
    Abstract: The present invention relates to a method for predicting the reactivity of a cancer-targeted therapeutic agent, in which various types of target proteins targeted by a cancer-targeted therapeutic agent are simultaneously quantified through triple quadrupole mass spectrometry. The inventors of the present invention carefully selected peptide sequences with high selectivity in nanoflow liquid chromatography-triple quadrupole mass spectrometry, in response to clinical needs, and optimized peptide combinations and experimental conditions to enable multiple peptide quantification.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 14, 2024
    Applicant: NATIONAL CANCER CENTER
    Inventors: Hark Kyun KIM, Yu Ri CHOI
  • Publication number: 20240060142
    Abstract: An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.
    Type: Application
    Filed: June 22, 2023
    Publication date: February 22, 2024
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Makiko YOSHIMOTO, Hiroko SUDO, Satoko KOZONO, Junpei KAWAUCHI, Takahiro OCHIYA, Hiroyuki FUJIMOTO, Wataru USUBA, Juntaro MATSUZAKI
  • Publication number: 20240058405
    Abstract: The present disclosure relates to a composition for preventing or treating lung cancer, comprising a compound isolated from a Cephalotaxus extract as an active ingredient. Isoharringtonine, which is the compound isolated from the Cephalotaxus extract according to the present disclosure, induces apoptosis and exhibits the effect of inhibiting the growth of non-small cell lung cancer cell lines, and thus can be useful in the prevention or treatment of lung cancer. In addition, the combined treatment of isoharringtonine and siNR4A1 enhances anticancer activity, and the combined treatment of isoharringtonine and cisplatin, which is a conventional anticancer drug, induces a high anticancer effect at a low concentration of cisplatin, thereby reducing side effects of anticancer treatment.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 22, 2024
    Applicants: NATIONAL CANCER CENTER, NATIONAL INSTITUTE FOR KOREAN MEDICINE DEVELOPMENT
    Inventors: Kyung Sil YOON, Yong Nyun KIM, Jae Gal SHIM, Dong Hoon SHIN, Hyo Jung KIM, Myoung Lae CHO, Soo Hyun KIM
  • Patent number: 11906536
    Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: February 20, 2024
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Hiroko Sudo, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
  • Patent number: 11905565
    Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: November 17, 2022
    Date of Patent: February 20, 2024
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Makiko Yoshimoto, Hiroko Sudo, Atsuko Miyano, Satoko Kozono, Takahiro Ochiya, Hiroyuki Fujimoto, Fumihiko Urabe, Juntaro Matsuzaki
  • Publication number: 20240052429
    Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 15, 2024
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi KONDOU, Hitoshi NOBUMASA, Satoko KOZONO, Hiroko SUDO, Junpei KAWAUCHI, Atsushi OCHIAI, Motohiro KOJIMA
  • Patent number: 11897954
    Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 13, 2024
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki Tenda, Masatoshi Yuri, Daisuke Yamajuku, Takeshi Tsutsumi, Yuko Kusuzaki, Hiroki Sasaki, Fumiko Chiwaki, Masayuki Komatsu
  • Patent number: 11901043
    Abstract: Disclosed is a sequence analysis method for analyzing nucleic acid sequence, the sequence analysis method including: obtaining a plurality of read sequences read from the nucleic acid sequence; and determining each nucleic acid sequence by aligning each read sequence with reference to a single reference sequence, wherein the reference sequence includes at least a first rearrangement sequence and a second rearrangement sequence that is different from the first rearrangement sequence.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 13, 2024
    Assignees: National Cancer Center, Mitsui Knowledge Industry Co., Ltd., Sysmex Corporation
    Inventors: Mamoru Kato, Hideya Kuwabara, Tomohiro Sakuma, Fumio Inoue, Kenichiro Suzuki